Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin and Gentamicin Serum Concentrations in Severe Sepsis
NCT02898961Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amikacin and gentamicin in sepsis, sponsored by CHU Nîmes. Primary endpoint: Presence/absence of target peak serum concentration of aminosides. Started Oct 2014; status: completed.
02
Drugs
amikacingentamicin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02898961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898961.